OpenEvidence, the rapidly growing AI platform often described as “ChatGPT for doctors,” has secured $200 million in new funding, valuing the company at $6 billion, according to The New York Times. The round follows a $210 million raise just three months ago at a $3.5 billion valuation, underscoring surging investor demand for specialized AI tools in healthcare.
The round was led by Google Ventures, with participation from Sequoia Capital, Kleiner Perkins, Blackstone, Thrive Capital, Coatue Management, Bond, and Craft.
Founded in 2022, OpenEvidence leverages advanced AI models trained on leading medical journals, including JAMAand The New England Journal of Medicine, to help clinicians access accurate, evidence-based answers in real time. The platform, free for verified medical professionals and supported by advertising, now facilitates over 15 million clinical consultations per month—nearly double its July total—positioning OpenEvidence as a frontrunner in the AI-driven transformation of modern healthcare.
